ProVIDE II Bridging Study

Exclusion Criteria

• •1. Void volume \<125 ml; Qmax \> 12 ml/s; PVR \> 250 ml
• •2. Obstructive median lobe defined by EITHER \>10mm protrusion on sagittal mid-prostate plane as measured by TRUS OR an obstructive median lobe seen on cystoscopy e.g., 'ball valve''
• •3. High bladder neck, with the absence of lateral lobe encroachment indicating a high likelihood of primary bladder neck obstruction
• •4. Anatomy that would prevent the apices of the ProVee from engaging with the lateral lobes e.g., high degree of bladder neck angulation such that the anterior bladder neck is not visible
• •5. Acute urinary retention
• •6. Known immunosuppression
• •7. History of or suspected prostate or bladder cancer
• •8. Baseline PSA \> 10 ng/mL or confirmed or suspected prostate cancer (Subjects with a PSA level above 2.5 ng/mL, or age specific, or local reference ranges should have prostate cancer excluded to the Investigator's satisfaction, including a SOC biopsy if indicated).
• •9. Recent urinary tract stones OR widespread calcifications on the prostatic urethral wall, within 3 months of index procedure
• •10. A history of prostatitis within the last two years
• •11. Active or history of epididymitis within the past 3 months
• •12. Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes
• •13. History of urinary retention within 12 months of baseline assessment
• •14. Requiring self-catheterization to void
• •15. An active urinary tract infection (UTI) at time of index procedure
• •16. Gross haematuria, within 3 months of index procedure.
• •17. Subjects with known allergy to nickel or titanium
• •18. Life expectancy estimated to be less than 60 months
• •19. Taking androgens, unless eugonadal state for at least 3 months or greater with a stable dosage for at least 2 months as documented by the Investigator
• •20. Use of 5-alpha-reductase inhibitors (e.g., dutasteride, finasteride) within 6 months of baseline assessment
• •21. Use of Phenylephrine / Pseudoephedrine within 24 hours of baseline assessment
• •22. Use of alpha-blockers (e.g., Terazosin, Doxazosin, Alfuzosin, Tamsulosin) within 2 weeks of baseline assessment
• •23. Use of estrogen or drug-producing androgen suppression (e.g. gonadotropin-releasing hormonal analogues) within 1 year of baseline assessment
• •24. Use of antihistamines, anticonvulsants, and antispasmodics within 1 week of baseline assessment unless there is documented evidence that the patient was on the same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued for entrance into or throughout the study)
• •25. Use of anticholinergics or cholinergic medication within 2 weeks of baseline assessment
• •26. Use of beta-blockers where the dose is not stable. (Stable dose is defined as having the same medication and dose in the last 6 months)
• •27. Use of Phosphodiesterase-5 Enzyme Inhibitors in doses for BPH within 2 weeks of baseline assessment.
• •28. Current treatment with anticoagulants (e.g., coumadin or enoxaparin) or antiplatelet medications other than aspirin (e.g., clopidogrel, or alternative and ASA). Patient unable to stop taking anticoagulants and/or antiplatelets within 3 days prior to the procedure or coumadin at least 5 days prior to the procedure. Low dose aspirin ≤100mg/day not prohibited
• •29. Future fertility concerns
• •30. Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate; including penile implants
• •31. Previous pelvic irradiation or radical pelvic surgery
• •32. Previous rectal surgery (other than haemorrhoidectomy) or known history of rectal disease
• •33. Urethral strictures, bladder neck contracture, or other potentially confounding bladder pathology
• •34. Urethral pathologies that may prevent insertion of Delivery System
• •35. Uncontrolled diabetes mellitus including Hgb AIC \>8%
• •36. Overactive bladder (OAB) requiring treatment by OAB medication
• •37. Urinary incontinence
• •38. Patients taking tri-cyclic antidepressants.
• •39. Compromised renal function (i.e., serum creatinine \>1.8 mg/dl or upper tract disease)
• •40. Hepatic disorder, bleeding disorders or metabolic impairment that might confound the results of the study or have a risk to subject per investigator's opinion
• •41. Any major comorbidities or presence of unstable conditions, e.g., uncontrolled HTN, NYHA Class III or IV, cardiac arrhythmias that are not controlled by medication/medical device, myocardial infarction within the past 6 months, COPD with FEV1 \<50, renal illness that might prevent study completion or would confound study results
• •42. Vulnerable populations such as incarcerated or institutionalized adults, inmates, patients with physical, psychological (such as developmentally delayed adults), or medical impairment that might, in the judgment of the Investigator, prevent study completion or comprehension, or may confound study results (including patient questionnaires)
• •43. History or current medical condition that would result in an unacceptable patient risk if that subject were to be included in the study
• •44. Any subject that is currently enrolled in another ongoing investigational study.